Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 22/11/2020
SIETES contiene 93161 citas

 1 a 20 de 68 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Addis A, Ganazzani A, Trotta MP, Magrini N, for the Italian Medicines Agency Scientific Committee and COVID-19 Crisis Unit. Promoting better clinical trials and drug information as public health interventions for the COVID-19 emergency in Italy. Ann Intern Med 2020:16 de junio. [Ref.ID 103673]
3. Cita con resumen
Wicks P, Vaughan T, Heywood J. Subjects no more: what happens when trial participants realise they hold the power?. BMJ 2014;348:g368. [Ref.ID 97217]
4. Cita con resumen
Berwanger O, Guimaraes HP, Laranjeira LN, Cavalcanti AB, Kodama AA, Zazula AD, Santucci EV, Victor E, Tenuta M, Carvalho V, Mira VL, Pieper KS, Weber B, Mota LH, Peterson ED, Lopes RD, for the BRIDGE-ACS Investigators. Effect of a multifaceted intervention on use of evidence-based therapies in patients with acute coronary syndromes in Brazil: The BRIDGE-ACS randomized trial. JAMA 2012;307:2041-9. [Ref.ID 93066]
5. Cita con resumen
6. Cita con resumen
Young RC. Cancer clinical trials - A chronic but curable crisis. N Engl J Med 2010;363:306-9. [Ref.ID 88945]
7. Cita con resumen
Anónimo. Improving the conduct of cancer trials in the USA. Lancet 2010;375:1408. [Ref.ID 88410]
9. Cita con resumen
The InFACT Global H1N1 Collaboration. InFACT: a global critical care research response to H1N1. Lancet 2010;375:11-3. [Ref.ID 87526]
10.Enlace a cita original
Carleton BC, Poole RL, Smith MA, Leeder JS, Ghannadan R, Ross CJD, Phillips MS, Hayden MR. Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals. Pharmacoepidemiol Drug Saf 2009;18:713-21. [Ref.ID 86509]
11.Tiene citas relacionadas
12.Tiene citas relacionadas Cita con resumen
Fergusson D. Inappropriate referencing in research. BMJ 2009;339:184-5. [Ref.ID 86394]
13.Tiene citas relacionadas Cita con resumen
Smith G. Happiness networks. What about social politics?. BMJ 2009;338:253. [Ref.ID 85151]
14.Tiene citas relacionadas Cita con resumen
Mellon JA. Happiness networks. Know your frieds. BMJ 2009;338:252-3. [Ref.ID 85150]
Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, Rochon J, for the DILIN Study Group. Drug-induced liver injury network (DILIN) prospective study: rationale, design and conduct. Drug Saf 2009;32:55-68. [Ref.ID 85096]
16.Tiene citas relacionadas Cita con resumen
Sainsbury P. Commentary: understanding social network analysis. BMJ 2009;338:27-8. [Ref.ID 84975]
18. Cita con resumen
Williams RL, Johnson SB, Greene SM, Larson EB, Green LA, Morris A, Confer D, Reaman G, Madigan R, Kahn J, for the Principal Investigators of the Clinical Research Networks Initiative. Signposts along the NIH roadmap for reengineering clinical research. Lessons from the Clinical Research Networks initiative. Arch Intern Med 2008;168:1919-25. [Ref.ID 84105]
Salanti G, Kavvoura FK, Ioannidis JPA. Exploring the geometry of treatment networks. Ann Intern Med 2008;148:544-53. [Ref.ID 82611]
20.Enlace a cita original Cita con resumen
Seleccionar todas
 1 a 20 de 68 siguiente >>